Vera Therapeutics Advances Atacicept with Promising Trial Results
Company Announcements

Vera Therapeutics Advances Atacicept with Promising Trial Results

Vera Therapeutics ( (VERA) ) has provided an announcement.

Vera Therapeutics announced promising long-term results from their Phase 2b ORIGIN trial, showcasing atacicept’s potential in treating IgAN, a chronic kidney disease. The data revealed significant reductions in proteinuria and improved kidney function stability over 96 weeks, suggesting atacicept’s ability to modify the disease’s progression. With these results, Vera aims to advance to a Phase 3 trial and plans to file a BLA with the FDA in 2025, potentially positioning atacicept as a leading treatment option in 2026.

See more data about VERA stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyVera Therapeutics partners with University of Michigan on NEPTUNE match project
TipRanks Auto-Generated NewsdeskVera Therapeutics Advances in Autoimmune Treatment
TheFlyVera Therapeutics reports Q3 EPS (85c), consensus (66c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App